Get the Stockscreener App
7.76
7.40%
-0.62
After Hours:
7.63
-0.13
-1.68%
Immunitybio Inc stock is traded at $7.76, with a volume of 18.68M.
It is down -7.40% in the last 24 hours and up +13.12% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.38
Open:
$7.815
24h Volume:
18.68M
Relative Volume:
0.74
Market Cap:
$8.13B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.91
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+9.30%
1M Performance:
+13.12%
6M Performance:
+264.32%
1Y Performance:
+310.58%
1-Day Range:
$7.36
$8.11
1-Week Range:
$6.94
$8.39
52-Week Range:
$1.91
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.76 | 8.78B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
425.00 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.10 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.31 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.00 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX Stock Slides As FDA Warning Triggers Class Action Heat - StocksToTrade
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum - Benzinga
ImmunityBio Stock (IBRX) Opinions on Q1 Earnings Release - Quiver Quantitative
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - marketscreener.com
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year - PharmiWeb.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox - The Globe and Mail
IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoil - MSN
IBRX Stock Could Snap 6-Day Winning Streak On Wider Q1 Loss – But Retail Traders Aren't Backing Down - Stocktwits
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt - Financial Times
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio Inc (NASDAQ:IBRX) Q1 Revenue Beat Overshadowed by Wider Losses and Stock Decline - ChartMill
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
ImmunityBio: Q1 Earnings Snapshot - marketscreener.com
ImmunityBio (NASDAQ: IBRX) boosts Q1 sales but records $632.8M loss - Stock Titan
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Millio - Business Wire
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Lawsuit Alleges Company Allegedly Violated Drug - GlobeNewswire
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny By Investing.com - Investing.com South Africa
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026 - The Globe and Mail
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
IBRX Stock Climbs As ANKTIVA Growth And Global Rollout Accelerate - StocksToTrade
Why ImmunityBio Stock Is Surging On Wednesday? - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX stock climbs: Founder says AI robot built to mass-produce cancer-killing immune cells ships this month - MSN
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX Stock Climbs: Founder Says AI Robot Built To Mass-Produce Cancer-Killing Immune Cells Ships This Month - Stocktwits
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - ACCESS Newswire
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
IBRX Lead Plaintiff Deadline is May 26, 2026Injured Stockholde - The National Law Review
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
2026-05-05 | IBRX Lead Plaintiff Deadline is May 26, 2026Injured Stockholders Should Contact Robbins LLP for Information About Their Rights Against ImmunityBio, Inc | NDAQ:IBRX | Press Release - Stockhouse
IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week - MSN
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting - BioSpace
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):